ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$11.86 USD
+0.56 (4.96%)
Updated Aug 6, 2024 04:00 PM ET
1-Strong Buy of 5 1
F Value B Growth F Momentum D VGM
Adma Biologics (ADMA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.75 | $16.00 | $10.00 | 15.94% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Adma Biologics comes to $13.75. The forecasts range from a low of $10.00 to a high of $16.00. The average price target represents an increase of 15.94% from the last closing price of $11.86.
Analyst Price Targets (4 )
Broker Rating
Adma Biologics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
6/20/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
5/10/2024 | Raymond James | Gary Nachman | Strong Buy | Strong Buy |
3/26/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $13.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | 0.08 |